OTCMKTS:RPBC - Redpoint Bio Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.0012 0.00 (0.00 %)
(As of 05/23/2018 06:00 AM ET)
Previous Close$0.0012
Today's Range$0.0006 - $0.0012
52-Week Range$0.0006 - $0.0022
Volume130,000 shs
Average Volume29,687 shs
Market Capitalization$100,000.00
P/E RatioN/A
Dividend YieldN/A

About Redpoint Bio (OTCMKTS:RPBC)

Redpoint Bio Corporation, a development stage biotechnology company, focuses on the development of healthier foods and new approaches for the treatment of diabetes and obesity by understanding the biology of taste and its relationship to metabolism, satiety, and diabetes. It enters into a license and commercialization agreement with International Flavors and Fragrances Inc. for the development, manufacture, use, and commercialization of RP44, which is a component of the stevia plant that works as a sweetness enhancer amplifying the existing sugary sweetness in a food or beverage. The company is based in Philadelphia, Pennsylvania.

Receive RPBC News and Ratings via Email

Sign-up to receive the latest news and ratings for RPBC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Commercial physical research


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A


Outstanding Shares79,920,000

Redpoint Bio (OTCMKTS:RPBC) Frequently Asked Questions

What is Redpoint Bio's stock symbol?

Redpoint Bio trades on the OTCMKTS under the ticker symbol "RPBC."

Who are some of Redpoint Bio's key competitors?

Who are Redpoint Bio's key executives?

Redpoint Bio's management team includes the folowing people:
  • Dr. R. Kyle Palmer Ph.D., Sr. Director of Discovery Research

Has Redpoint Bio been receiving favorable news coverage?

News stories about RPBC stock have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Redpoint Bio earned a daily sentiment score of 0.09 on Accern's scale. They also gave news headlines about the company an impact score of 47.80 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near term.

How do I buy shares of Redpoint Bio?

Shares of RPBC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Redpoint Bio's stock price today?

One share of RPBC stock can currently be purchased for approximately $0.0012.

How big of a company is Redpoint Bio?

Redpoint Bio has a market capitalization of $100,000.00.

How can I contact Redpoint Bio?

Redpoint Bio's mailing address is 7 GRAPHICS DRIVE, EWING NJ, 08628. The company can be reached via phone at 215-456-2312.

MarketBeat Community Rating for Redpoint Bio (RPBC)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  22 (Vote Outperform)
Underperform Votes:  23 (Vote Underperform)
Total Votes:  45
MarketBeat's community ratings are surveys of what our community members think about Redpoint Bio and other stocks. Vote "Outperform" if you believe RPBC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RPBC will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Redpoint Bio (OTCMKTS:RPBC) Analyst Ratings History

DateBrokerageActionRatingPrice TargetDetails
(Data available from 5/23/2016 forward)


Redpoint Bio (OTCMKTS:RPBC) Earnings History and Estimates Chart

Earnings by Quarter for Redpoint Bio (OTCMKTS:RPBC)

Redpoint Bio (OTCMKTS RPBC) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/16/2011Q1 2011($0.01)ViewN/AView Earnings Details
3/4/2011Q4 2010($0.02)($0.01)ViewN/AView Earnings Details
11/9/2010Q3 2010($0.02)($0.02)ViewN/AView Earnings Details
8/13/2010Q2 2010($0.02)($0.02)ViewN/AView Earnings Details
5/14/2010Q1 2010($0.02)ViewN/AView Earnings Details
3/29/2010Q4 2009($0.02)ViewN/AView Earnings Details
11/12/2009Q3 2009($0.03)ViewN/AView Earnings Details
8/13/2009Q2 2009($0.03)ViewN/AView Earnings Details
5/14/2009Q1 2009($0.03)ViewN/AView Earnings Details
3/26/2009Q4 2008($0.02)ViewN/AView Earnings Details
11/7/2008Q3 2008($0.03)($0.03)ViewN/AView Earnings Details
8/8/2008Q2 2008($0.03)($0.03)ViewN/AView Earnings Details
5/9/2008Q1 2008($0.03)ViewN/AView Earnings Details
3/10/2008Q4 2007($0.02)($0.02)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)


Redpoint Bio (OTCMKTS:RPBC) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Redpoint Bio (OTCMKTS RPBC) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 11.51%
Insider Trading History for Redpoint Bio (OTCMKTS:RPBC)

Redpoint Bio (OTCMKTS RPBC) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)


Redpoint Bio (OTCMKTS RPBC) News Headlines

No headlines for this company have been tracked by MarketBeat.com

SEC Filings

Redpoint Bio (OTCMKTS:RPBC) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


Financials are not available for this stock.


Redpoint Bio (OTCMKTS RPBC) Stock Chart for Wednesday, May, 23, 2018

Loading chart…

This page was last updated on 5/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.